Evofem Biosciences, Inc. (EVFM)
Chart Events
Performance Outlook
| Previous Close | 0.3830 |
| Open | 0.3828 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 3100 |
| Day's Range | 0.3737 - 0.4600 |
| 52 Week Range | 0.2750 - 14.6100 |
| Volume | |
| Avg. Volume | 36,554,109 |
| Market Cap | 35.295M |
| Beta (5Y Monthly) | -1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.0060 |
| Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.05 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EVFM
Related Research
- Evofem Biosciences, Inc.Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.RatingFair ValueEconomic Moatlast yearMorningstar
- PR Newswire
Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:
- ACCESSWIRE
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences.
- Benzinga
Evofem Clocks 42% Growth For Its On-Demand Birth Control Product
Evofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%. The company's operating expense was reduced by 8% to $30 million and improved loss from operations by 16% to $(24) million. The U.S. government clarified that it would enforce federal law requiring group health plans and health insurance issuers to cover contraception at no cost to participants. In June, Evofem announced an agree
